109346-84-1

Usage

Appearance

Yellowish liquid The compound has a yellowish color and is in a liquid state at room temperature.

Usage as an intermediate

Synthesis of pharmaceuticals and agrochemicals 2-(3,4-difluorophenyl)acetaldehyde is commonly used in the production of various drugs and chemicals used in agriculture.

Reagent in organic chemistry

Utilized in various transformations The compound is used as a reagent to create new carbon-carbon and carbon-heteroatom bonds in organic chemistry reactions.

Key building block

Preparation of numerous fine chemicals 2-(3,4-difluorophenyl)acetaldehyde serves as an important component in the synthesis of a wide range of specialized chemical products.

Versatile starting material

Production of complex organic molecules The compound is often employed as a starting material for creating more intricate organic compounds due to its chemical properties and reactivity.

Upstream product

• 658-93-5 (3,4-difluorophenyl)acetic acid 
• 286440-92-4 2-(3,4-difluorophenyl)ethan-1-ol 
• 129409-55-8 ethyl 2-(3,4-difluorophenyl)acetate 
• 371162-64-0 1-methoxy-2-(3,4-difluorophenyl)ethane 
• 872046-03-2 1,2-difluoro-4-(2-methoxy-vinyl)-benzene 

Relevant academic research and scientific papers

Synthesis of trans-2-Substituted Cyclopropylamines from α-Chloroaldehydes

Cyclopropylamines are prevalent in pharmaceuticals and agrochemicals. Herein, we report the synthesis of trans-2-substituted cyclopropylamines in high diastereoselectivity from readily available α-chloroaldehydes. The reaction proceeds via trapping of an electrophilic zinc homoenolate with an amine followed by ring closure to generate the cyclopropylamine. We have also observed that cyclopropylamine cis/trans-isomerization occurs in the presence of zinc halide salts and that this process can be turned off by the addition of a polar aprotic cosolvent.

Novel Hypoxia-Inducible Factor 1α (HIF-1α) Inhibitors for Angiogenesis-Related Ocular Diseases: Discovery of a Novel Scaffold via Ring-Truncation Strategy

Ocular diseases featuring pathologic neovascularization are the leading cause of blindness, and anti-VEGF agents have been conventionally used to treat these diseases. Recently, regulating factors upstream of VEGF, such as HIF-1α, have emerged as a desirable therapeutic approach because the use of anti-VEGF agents is currently being reconsidered due to the VEGF action as a trophic factor. Here, we report a novel scaffold discovered through the complete structure-activity relationship of ring-truncated deguelin analogs in HIF-1α inhibition. Interestingly, analog 6i possessing a 2-fluorobenzene moiety instead of a dimethoxybenzene moiety exhibited excellent HIF-1α inhibitory activity, with an IC50 value of 100 nM. In particular, the further ring-truncated analog 34f, which showed enhanced HIF-1α inhibitory activity compared to analog 2 previously reported by us, inhibited in vitro angiogenesis and effectively suppressed hypoxia-mediated retinal neovascularization. Importantly, the heteroatom-substituted benzene ring as a key structural feature of analog 34f was identified as a novel scaffold for HIF-1α inhibitors that can be used in lieu of a chromene ring.

3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS

Disclosed are chemical entities of Formula (I): wherein X, Y, Z, R1, R3, R4 and R5 are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).

NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS

There is provided compounds of formula I, [Chemical formula should be inserted here. Please see paper copy] wherein R1 to R4 , R41 to R46 and Z have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias

NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS

There is provided compounds of formula (I), wherein R1, R2, R3, R4, R 41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

Cyclohexane derivatives, liquid crystal compositions comprising the same and liquid crystal display devices

Liquid crystalline compounds are disclosed which have large dielectric anisotropy and relatively low viscosity, and which are represented by formula (1) wherein R1 represents hydrogen or C1-C15 alkyl in which one or more n